SCHEMBL25669294

SCHEMBL25669294

BCCC(CCOC)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7094163 0.87
SCHEMBL25669293 0.82
SCHEMBL28223236 0.77
SCHEMBL12580946 0.76 CYP2C9 (0.30)
SCHEMBL6223856 0.75 GABBR2 (0.30)
SCHEMBL6130621 0.75 PIK3CD (0.38)
SCHEMBL11703774 0.75
SCHEMBL10525106 0.74
SCHEMBL28144888 0.74
SCHEMBL10282921 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230340485-A1 ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF ALNYLAM PHARMACEUTICALS, INC. (US) 2023-10-26 US disclosed
US-20230295622-A1 COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION ALNYLAM PHARMACEUTICALS, INC. (US) 2023-09-21 US disclosed
US-20230256001-A1 MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT ALNYLAM PHARMACEUTICALS, INC. (US) 2023-08-17 US disclosed
US-20230190785-A1 COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION ALNYLAM PHARMACEUTICALS, INC. (US) 2023-06-22 US disclosed